deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02138786

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation (SIRRT)

A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Initial or Refractory and/or Relapsed Richter's Transformation (RT)

Sponsor: Karyopharm Therapeutics Inc

Conditions Richter's Transformation
Interventions selinexor
Updated 17 times since 2017 Last updated: Jan 24, 2023 Started: Nov 14, 2014 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of efficacy at time of interim analysis

Other terminated trials from Karyopharm Therapeutics Inc

More terminations from Karyopharm Therapeutics Inc

Listed as NCT02138786, this PHASE2 trial focuses on Richter's Transformation and remains terminated or withdrawn. Sponsored by Karyopharm Therapeutics Inc, it has been updated 17 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Mar 2020 · 19 months · monthly snapshot~Mar 2020 – ~Oct 2020 · 7 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Feb 2023 · 14 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Feb 2023 [monthly]

    Terminated PHASE2

▶ Show 12 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Mar 2020 — Oct 2020 [monthly]

    Terminated PHASE2

  4. Aug 2018 — Mar 2020 [monthly]

    Terminated PHASE2

  5. Jul 2018 — Aug 2018 [monthly]

    Terminated PHASE2

  6. Jun 2018 — Jul 2018 [monthly]

    Terminated PHASE2

  7. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  8. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  9. Jul 2017 — Aug 2017 [monthly]

    Terminated PHASE2

  10. May 2017 — Jul 2017 [monthly]

    Terminated PHASE2

  11. Feb 2017 — May 2017 [monthly]

    Terminated PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Karyopharm Therapeutics Inc
Data source: Karyopharm Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Cologne, Germany , Columbus, United States , Duarte, United States , Krakow, Poland , Lodz, Poland , New York, United States , Oxford, United Kingdom , Pamplona, Spain and 6 more locations